我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
40
10 进行中
药物批准
10
批准总数
监管机构
1
监管机构数
成立时间
2001
进行中（未招募）
3
7.5%
已完成
4
10.0%
尚未招募
7
17.5%
招募中
14
35.0%
终止
2.5%
Unknown
11
27.5%
NMPA
National Medical Products Administration
- Hengrui Pharma and its subsidiaries received NMPA clinical trial approvals for five oncology drugs, including HRS-6093, a novel oral KRAS G12D inhibitor with no similar approved products globally. - The approved pipeline includes SHR-9839, a dual-pathway blocking humanized antibody, and SHR-1826, a c-Met targeting antibody-drug conjugate with cumulative R&D investments totaling over RMB 400 million. - The company's adalimumab injection, already approved for small cell lung cancer treatment in 2023, received additional clinical trial approval alongside SHR-8068, an anti-CTLA-4 monoclonal antibody. - Total cumulative R&D investment across all five programs amounts to approximately RMB 789.27 million, reflecting significant commitment to oncology drug development.
